MA52288A - Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci - Google Patents

Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci

Info

Publication number
MA52288A
MA52288A MA052288A MA52288A MA52288A MA 52288 A MA52288 A MA 52288A MA 052288 A MA052288 A MA 052288A MA 52288 A MA52288 A MA 52288A MA 52288 A MA52288 A MA 52288A
Authority
MA
Morocco
Prior art keywords
compositions
methyl modification
modification enzyme
enzyme modulators
modulators
Prior art date
Application number
MA052288A
Other languages
English (en)
Other versions
MA52288B1 (fr
Inventor
Alexandre Côté
Victor S Gehling
Avinash Khanna
Ludivine Moine
Jacob I Stuckey
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of MA52288A publication Critical patent/MA52288A/fr
Publication of MA52288B1 publication Critical patent/MA52288B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
MA52288A 2018-04-18 2019-04-17 Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci MA52288B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659408P 2018-04-18 2018-04-18
EP19722363.9A EP3781561B1 (fr) 2018-04-18 2019-04-17 Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
PCT/US2019/027932 WO2019204490A1 (fr) 2018-04-18 2019-04-17 Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci

Publications (2)

Publication Number Publication Date
MA52288A true MA52288A (fr) 2021-04-07
MA52288B1 MA52288B1 (fr) 2024-07-31

Family

ID=66429588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52288A MA52288B1 (fr) 2018-04-18 2019-04-17 Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci

Country Status (34)

Country Link
US (3) US10689371B2 (fr)
EP (2) EP3781561B1 (fr)
JP (2) JP7256823B2 (fr)
KR (2) KR102798145B1 (fr)
CN (2) CN119954787A (fr)
AR (1) AR114793A1 (fr)
AU (1) AU2019255310B2 (fr)
BR (1) BR112020021194A2 (fr)
CL (1) CL2020002698A1 (fr)
CO (1) CO2020014217A2 (fr)
CR (1) CR20200553A (fr)
DK (1) DK3781561T3 (fr)
EA (1) EA202092490A1 (fr)
ES (1) ES2983344T3 (fr)
FI (1) FI3781561T3 (fr)
HR (1) HRP20240793T1 (fr)
HU (1) HUE066783T2 (fr)
IL (1) IL278013B2 (fr)
LT (1) LT3781561T (fr)
MA (1) MA52288B1 (fr)
MD (1) MD3781561T2 (fr)
MX (1) MX2020010999A (fr)
MY (1) MY208662A (fr)
PE (1) PE20201448A1 (fr)
PH (1) PH12020551578A1 (fr)
PL (1) PL3781561T3 (fr)
PT (1) PT3781561T (fr)
RS (1) RS65621B1 (fr)
SG (1) SG11202009438UA (fr)
SI (1) SI3781561T1 (fr)
SM (1) SMT202400233T1 (fr)
TW (1) TWI828677B (fr)
UA (1) UA127357C2 (fr)
WO (1) WO2019204490A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021194A2 (pt) * 2018-04-18 2021-03-23 Constallation Pharmaceuticals, Inc. moduladores de enzimas modificadoras de metila, composições e usos dos mesmos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
ES2997972T3 (en) 2019-07-24 2025-02-18 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
KR20220041130A (ko) * 2019-07-24 2022-03-31 콘스텔레이션 파마슈티칼스, 인크. 암 치료를 위한 병용 요법에서의 ezh2 억제
US20230365541A1 (en) * 2020-03-13 2023-11-16 Haisco Pharmaceuticals Pte. Ltd. Inhibitor of enhancer of zeste homologue 2, and use thereof
CN113666920B (zh) * 2020-04-14 2025-10-03 浙江华海药业股份有限公司 苯并恶唑类化合物制备方法及其在医药领域的应用
EP4180426A4 (fr) * 2020-07-08 2024-08-07 Daiichi Sankyo Company, Limited Procédé de production d'un dérivé de 1,3-benzodioxole
EP4247371B1 (fr) * 2020-11-18 2025-01-01 Constellation Pharmaceuticals, Inc. Thérapies d'inhibition de l'ezh2 pour le traitement de cancers de la prostate ayant subi une mutation du récepteur des androgènes
KR102872076B1 (ko) 2021-01-11 2025-10-15 주식회사 엘지에너지솔루션 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법
JP7799847B6 (ja) * 2022-01-14 2026-02-10 トンファ ファーム カンパニー リミテッド １，３－ベンゾジオキソール誘導体化合物およびそれを含む薬剤学的組成物
CN116496263A (zh) * 2022-01-27 2023-07-28 江苏天士力帝益药业有限公司 Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用
WO2023217018A1 (fr) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Inhibiteur d'ezh2 et son utilisation en médecine
JP2025525324A (ja) 2022-06-13 2025-08-05 ツリーライン バイオサイエンシズ インコーポレイテッド １，８－ナフチリジン－２－オンヘテロ二官能性ｂｃｌ６分解剤
IL317228A (en) 2022-06-13 2025-01-01 Treeline Biosciences Inc BCL6 quinolone bifunctional joints
IL318787A (en) 2022-08-17 2025-04-01 Incyte Corp Treatment including ANTI-CD19 antibodies and EZH2 modulators
CN121712510A (zh) * 2023-07-06 2026-03-20 同和药品株式会社 包含1,3-苯并间二氧杂环戊烯衍生物化合物的药物组合物
TW202542136A (zh) * 2023-12-15 2025-11-01 大陸商格物生物技術（江蘇）有限公司 １，３－苯并二氧雜環戊烯衍生物以及其用途

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
DK611489A (da) 1988-12-08 1990-06-09 Duphar Int Res Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
ATE478672T1 (de) 1996-01-29 2010-09-15 Univ California Methode zur behandlung sexueller fehlfunktionen
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
PT1026950E (pt) 1997-10-27 2006-06-30 Cortex Pharma Inc Tratamento da esquizofrenia com ampaquinas e neurolepticos
CA2344169C (fr) 1998-09-29 2011-07-19 American Cyanamid Company Inhibiteurs de proteines de type tyrosine kinases a base de 3-cyanoquinolines substituees
EP1384713B1 (fr) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation Derives de 4-amino-azepan-3-one comme inhibiteurs de protease
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
KR100821446B1 (ko) 2000-08-21 2008-04-10 아스트라제네카 아베 퀴나졸린 유도체
WO2002016327A1 (fr) 2000-08-23 2002-02-28 The Procter & Gamble Company Benzimidazoles et analogues et utilisation de ces derniers comme inhibiteurs neutrophiles
US20020133019A1 (en) 2000-08-24 2002-09-19 Klunk William E. Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
EP1368024A4 (fr) 2001-03-16 2009-03-18 Novogen Res Pty Ltd Traitement de la restenose
EP1767525A1 (fr) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Composés guanidino comme agonistes du récepteur 4 de la mélanocortine (MC4-R)
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002367023A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2003059898A2 (fr) 2002-01-08 2003-07-24 Eisai Co. Ltd. Analogues d'eponemycine et d'epoxomicine et leurs utilisations
CA2473740A1 (fr) 2002-01-18 2003-07-31 David Solow-Cordero Procedes pour traiter des pathologies associees a un recepteur d'edg
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
EP1503751A4 (fr) 2002-04-09 2007-08-01 Novogen Res Pty Ltd Procedes therapeutiques et compositions associees contenant des structures isoflav-3-ene et isoflavan
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
NZ537685A (en) 2002-07-29 2007-06-29 Hoffmann La Roche Novel benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
CA2499602A1 (fr) 2002-09-23 2004-04-01 Graham Edmund Kelly Traitement du photovieillissement et de la deterioration actinique de la peau
US8106214B2 (en) 2003-07-28 2012-01-31 Merck Serono Sa 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
JP2007511542A (ja) 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
MXPA06005697A (es) 2003-11-19 2006-08-17 Novogen Res Pty Ltd Composiciones y metodos para radioterapia y quimioterapia en combinacion.
EP1711467A2 (fr) 2004-01-16 2006-10-18 Wyeth Intermediaires de quinoleine des inhibiteurs des recepteurs de tyrosine kinase et leur synthese
AR048528A1 (es) 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
JP4604086B2 (ja) 2004-05-07 2010-12-22 エグゼリクシス， インコーポレイテッド Ｒａｆモジュレーターおよびその使用方法
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
MX2007004302A (es) 2004-10-12 2007-06-07 Applied Research Systems Inhibidores de pi3 cinasa gamma para el tratamiento de anemia.
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
KR20070108270A (ko) 2005-02-28 2007-11-08 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 신규 병용
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
WO2006103449A2 (fr) 2005-03-31 2006-10-05 Astrazeneca Ab Composes
KR20070120182A (ko) 2005-04-08 2007-12-21 바이엘 파마슈티칼스 코포레이션 피리미딘 유도체 및 암의 치료에서의 이의 용도
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
KR20080016600A (ko) 2005-05-25 2008-02-21 와이어쓰 3-시아노-퀴놀린의 제조 방법 및 이에 의해 제조된 중간생성물
WO2006129609A1 (fr) 2005-05-30 2006-12-07 Shionogi & Co., Ltd. Derive 2-naphtylimino-5,5-disubstitue-1,3-thiazine
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
US20070093455A1 (en) 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
CN101277700B (zh) 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
WO2007020936A1 (fr) 2005-08-17 2007-02-22 Daiichi Sankyo Company, Limited Composé bicyclique hétérocyclique possédant une action fongicide
WO2007081630A2 (fr) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Inhibiteurs substitues de la pyrimidinyl kinase
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
NZ571271A (en) 2006-03-23 2011-10-28 Biota Europe Ltd The use of benzamide or pyridinamide derivatives as antibacterial agents
JP2009538866A (ja) 2006-05-30 2009-11-12 ノイロサーチ アクティーゼルスカブ 新規１，４−ジアザ−ビシクロ［３．２．２］ノニルオキサジアゾリル誘導体及びそれらの医学的使用
WO2008027648A2 (fr) 2006-06-26 2008-03-06 Case Western Reserve University Procédés et compositions pour traiter des pathologies associées à la signalisation du bdnf
WO2008029168A2 (fr) 2006-09-08 2008-03-13 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
EP2084141A4 (fr) 2006-10-30 2010-07-21 Novogen Res Pty Ltd Prévention et inversion de la neuropathie périphérique induite par une chimiothérapie
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
NZ580801A (en) 2007-05-10 2012-09-28 Bristol Myers Squibb Co Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
WO2009136995A2 (fr) 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibiteurs de la syk protéine kinase
JP5530430B2 (ja) 2008-06-23 2014-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｃｒ２のピペリジルアクリルアミドアンタゴニスト
EP2310378A2 (fr) 2008-08-14 2011-04-20 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxydes en tant qu'agents antischistosomiaux
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
TW201109327A (en) 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
AU2010270153A1 (en) 2009-07-10 2012-02-02 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis C NS5B polymerase, the pharmaceutical composition thereof and their therapeutic use
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2011084657A1 (fr) 2009-12-17 2011-07-14 The Lubrizol Corporation Composition lubrifiante contenant un composé aromatique
JP5833022B2 (ja) 2010-01-27 2015-12-16 エービー・ファーマ・リミテッド Ｃ型肝炎ウィルス阻害剤としてのポリ複素環式化合物
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
EP2580215A4 (fr) 2010-06-10 2014-01-15 Afraxis Holdings Inc 8-(hétérocycyl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc
DK2582674T3 (en) 2010-06-16 2014-12-15 Cymabay Therapeutics Inc GPR120 receptor agonists and uses thereof.
EP2598512A1 (fr) 2010-07-28 2013-06-05 Medizinische Universität Wien Dérivés de chalcone vinylogue et leur utilisation médicale
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
JPWO2012036278A1 (ja) 2010-09-17 2014-02-03 大正製薬株式会社 グリシントランスポーター阻害物質
WO2012045196A1 (fr) 2010-10-09 2012-04-12 Abbott Laboratories Inhibiteurs de la phosphoglycérate kinase
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
WO2013025484A1 (fr) 2011-08-12 2013-02-21 Lapchak Paul A Analogues de polyphénol pour traiter une ischémie
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013065835A1 (fr) 2011-11-04 2013-05-10 味の素株式会社 Composition pharmaceutique destinée au traitement du diabète
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
WO2014034898A1 (fr) 2012-08-30 2014-03-06 日本新薬株式会社 Dérivé de pyridine et médicament
CA2900335C (fr) 2012-10-22 2021-10-26 City Of Hope Analogues synthetiques d'epipolythiodioxopiperazines et leurs utilisations
MX2015011456A (es) 2013-03-13 2016-05-31 Boston Biomedical Inc Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.
EP2991963B1 (fr) 2013-04-30 2021-07-07 Heinrich-Heine-Universität Düsseldorf Inhibiteurs de la tétramérisation de nhr2 et/ou runx1/eto
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
CA2923522C (fr) 2013-09-09 2018-11-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Derive de glucoside de type c-aryle, son procede de preparation, et ses applications medicales
WO2015069110A1 (fr) 2013-11-07 2015-05-14 Aapa B.V. Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc
MX370676B (es) 2014-03-17 2019-12-19 Daiichi Sankyo Co Ltd Derivado de 1,3-benzodioxol.
MD4820C1 (ro) 2014-06-17 2023-03-31 Pfizer Inc. Compuşi dihidroizochinolinonici substituiţi
CA2960757C (fr) 2014-09-11 2022-09-06 Piramal Enterprises Limited Composes heterocycliques condenses a titre d'agonistes du gpr120
US20180037568A1 (en) * 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2017018499A1 (fr) 2015-07-30 2017-02-02 第一三共株式会社 Agent thérapeutique et/ou prophylactique pour lymphome/leucémie de lymphocyte t adulte
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
AU2017217536A1 (en) 2016-02-09 2018-08-09 Inventisbio Inc. Inhibitor of indoleamine-2,3-dioxygenase (IDO)
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018013789A1 (fr) 2016-07-14 2018-01-18 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
US11466020B2 (en) 2017-03-17 2022-10-11 Cornell University Compounds and compositions for inhibition and elimination of Zika infection and uses for same
MX2019013954A (es) 2017-05-25 2020-08-31 Araxes Pharma Llc Inhibidores covalentes de kras.
US12171755B2 (en) 2017-10-25 2024-12-24 Children's Medical Center Corporation PAPD5 inhibitors and methods of use thereof
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
JP2021510733A (ja) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
WO2019191558A1 (fr) 2018-03-30 2019-10-03 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Procédés visant à atténuer et de prévenir les lésions liées à la protéostase
BR112020021194A2 (pt) 2018-04-18 2021-03-23 Constallation Pharmaceuticals, Inc. moduladores de enzimas modificadoras de metila, composições e usos dos mesmos

Also Published As

Publication number Publication date
EA202092490A1 (ru) 2020-12-23
TWI828677B (zh) 2024-01-11
US20200317651A1 (en) 2020-10-08
US10689371B2 (en) 2020-06-23
SG11202009438UA (en) 2020-11-27
HRP20240793T1 (hr) 2024-09-13
TW202003505A (zh) 2020-01-16
EP4421072A1 (fr) 2024-08-28
HUE066783T2 (hu) 2024-09-28
PL3781561T3 (pl) 2024-07-22
KR102798145B1 (ko) 2025-04-22
DK3781561T3 (da) 2024-06-17
CL2020002698A1 (es) 2021-01-15
JP2021522166A (ja) 2021-08-30
US20190322651A1 (en) 2019-10-24
PT3781561T (pt) 2024-06-18
PE20201448A1 (es) 2020-12-10
IL278013A (en) 2020-11-30
SMT202400233T1 (it) 2024-07-09
US20240116905A1 (en) 2024-04-11
FI3781561T3 (fi) 2024-06-13
JP7256823B2 (ja) 2023-04-12
US11274095B2 (en) 2022-03-15
JP2023082132A (ja) 2023-06-13
MY208662A (en) 2025-05-22
KR20250073166A (ko) 2025-05-27
MX2020010999A (es) 2021-01-20
AU2019255310B2 (en) 2022-11-24
CR20200553A (es) 2021-04-08
SI3781561T1 (sl) 2024-08-30
CN111989325B (zh) 2025-02-25
CN111989325A (zh) 2020-11-24
AR114793A1 (es) 2020-10-14
PH12020551578A1 (en) 2021-09-13
EP3781561A1 (fr) 2021-02-24
AU2019255310A1 (en) 2020-10-15
MA52288B1 (fr) 2024-07-31
IL278013B1 (en) 2023-09-01
BR112020021194A2 (pt) 2021-03-23
UA127357C2 (uk) 2023-07-26
CO2020014217A2 (es) 2021-03-08
IL278013B2 (en) 2024-01-01
ES2983344T3 (es) 2024-10-22
MD3781561T2 (ro) 2025-02-28
KR20210003160A (ko) 2021-01-11
CN119954787A (zh) 2025-05-09
CA3098428A1 (fr) 2019-10-24
LT3781561T (lt) 2024-07-10
RS65621B1 (sr) 2024-07-31
WO2019204490A1 (fr) 2019-10-24
EP3781561B1 (fr) 2024-03-13

Similar Documents

Publication Publication Date Title
MA52288A (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
EP4047019A4 (fr) Anticorps anti-tslp et utilisations de celui-ci
EP3902834A4 (fr) Compositions hétérodimeres d'anticorps à spécifiques et à tétravalents, et utilisations de celles-ci
EP3875469A4 (fr) Nouvelle enzyme crispr/cas12f et système
EP4211234A4 (fr) Enzymes d'édition de base
EP3576737A4 (fr) Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte
EP3615019A4 (fr) Modulateurs de l'interaction sestrine-gator2 et utilisations de ces derniers
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
UY34645A (es) Control de microorganismos fitopatogénicos con pseudomonas sp. y sustancias y composiciones derivad as de las mismas
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
WO2019209885A3 (fr) Modification d'enzyme pour modifier le répertoire fonctionnel de synthases de cannabinoïdes
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
EP3969526A4 (fr) Composition de revêtement et ses utilisations
MA52485A (fr) Combinaisons de variants d'anticorps et utilisations associées
EP3864147A4 (fr) Ingénierie d'enzymes d'adnase pour la fabrication et la thérapie
EP4051283A4 (fr) Modulateurs de p53 et utilisations de ceux-ci
EP4074837A4 (fr) Enzyme daao modifiée et son application
EP3829520A4 (fr) Inhibiteurs de lysyl oxydases dérivés d'halogénoallylamine sulfone et utilisations associées
EP3781179A4 (fr) Enzymes kinuréninases humaines et utilisations associées
MA52200A (fr) Compositions de vaa, procédés de préparation et méthodes d'utilisation
IL287384A (en) Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
EP4370594A4 (fr) Enzymes et leurs utilisations
EP3673085A4 (fr) Méthodes de criblage d'enzyme
EP3906056A4 (fr) Anticorps agonistes de cd137 et utilisations associées
EP4021449A4 (fr) Modulateurs de sting, compositions et procédés d'utilisation